UBC Opens New Office in Tokyo
United BioSource Corporation (UBC; Bethesda, MD) announced the opening of its newest global office in Tokyo, Japan. The office will be led by Kumpei Kobayashi, PharmD, a biopharmaceutical industry veteran with over 20 years of product development experience throughout the Asia-Pacific region. Personnel in the new UBC office will support the company’s investigator training and certification solutions as well as ongoing clinical research monitoring services in the region.
“The UBC office in Tokyo will help us support our clients’ research projects with local personnel who understand the needs of patients, health care professionals and regulators in this important region. Local knowledge of the Asia-Pacific markets is absolutely essential when we help clients manage research projects that are often very large, complex and supported by significant financial investments,” said Catherine Spear, UBC’s Senior Vice President.
Dr. Kobayashi will be joined by several members of UBC’s management team, including David Miller, MD, who has served as a scientific leader on several Pan-Asian and multi-national studies involving sites in Japan, Taiwan, Korea, China, Hong Kong, India, Philippines, Singapore, and Thailand.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
Funding Cuts Threaten Diversity in Clinical Research
June 27th 2025In this video interview, Kyle McAllister, co-founder, CEO, Trially, discusses how recent federal funding cuts are likely to undermine research focused on underrepresented populations, and why long-term investment in community-based studies is essential to closing persistent health equity gaps.
Pfizer Reports Strong Phase III Results for Hympavzi in Hemophilia Patients with Inhibitors
June 26th 2025The Phase III BASIS trial found that once-weekly subcutaneous Hympavzi reduced treated bleed rates by 93% in patients with hemophilia A or B with inhibitors, offering a promising new prophylactic option for a population with limited therapeutic choices.
